AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06251180
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Trial: NCT06251180
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Trial: NCT06031844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral film-coated tablets
Trial: NCT04862221
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the high-dose methylprednisolone arm will receive an initial dose of methylprednisolone IV 10 mg/kg/day for 3 days and 5 mg/kg/day on Day 4. Normal saline will be used as placebo pre-medications and infusions given at the same volume and duration as the eATG infusions.
Trial: NCT04862221
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below.~Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue
Trial: NCT04862221
Drug: Placebo for prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 1 mg/kg/day of oral placebo for prednisolone on days 5-13 followed by a gradual taper to discontinuation at 42 days as indicated below. Subjects receiving oral placebo will be given a solution that closely resembles the treatment drug.~Days 5 - 13 Placebo for Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Placebo for Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Placebo for Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Placebo for Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Placebo for Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue
Trial: NCT04862221
Drug: Placebo for infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the supportive care alone arm will receive normal saline in place of all study treatments (skin test, premedication and IV infusions) on Days 1-4 given at the same volume and duration as the eATG infusions.
Trial: NCT05627375
Drug: Full-dose anticoagulant therapy (AC)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant (AC) therapy: at the investigator's discretion in accordance with international recommendations for the management of DVT/PE
Trial: NCT05627375
Drug: Antiplatelet therapy (AP)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)
Trial: NCT05254574
Drug: 2.5% Diclofenac Patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
Trial: NCT05030428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
Trial: NCT04354545
Drug: Xiidra (Lifitegrast ophthalmic solution) 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA approved lifitegrast opthalmic solution eye drop
Trial: NCT04667377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04592744
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
Trial: NCT05065463
Drug: AZD8233
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.
Trial: NCT05800873
Drug: EVER001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
Trial: NCT04794088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 25ml placebo (12.5ml/h).
Trial: NCT04979442
Drug: RAIN-32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
Trial: NCT05013034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given IV dosing with placebo (1/2 normal saline) up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
Trial: NCT04872400
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 vial of Tobramycin 1.2g powder applied topically to the open fracture wound injury.
Trial: NCT06066424
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by (IV) vein
Trial: NCT05529927
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group.
Trial: NCT05768919
Drug: Treatment Period 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV - Dose: per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 1,2, 3,4,5,6 Cycle length: 6 weeks~Agent: TMZ Premedications/Precautions No food 2 hr before and after dosing Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener PRN. Dose: 75 mg/m2 Route: Oral Schedule: Daily during term of RT Cycle Length: 6 weeks~Agent: Radiotherapy Premedications/Precautions: n/a Dose: 2 Gy Route: External beam therapy Schedule: Monday-Friday Cycle Length 6 weeks
Trial: NCT05768919
Drug: Treatment Period 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Adjuvant Cycles 11-34 Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks~Agent: TMZ Premedication/Precautions: No food 2 hr before and after dosing. Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener prn Dose: 150-200 mg/m2 (Cycles 1-6) Route: Oral Schedule: Daily Cycle Length: 4 weeks
Trial: NCT05548738
Drug: medthylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a type of steroids injected in epidural space
Trial: NCT05170828
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pre-transplant conditioning treatment
Trial: NCT05170828
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: post-transplant treatment for GVHD
Trial: NCT05593250
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous ,placebo
Trial: NCT05677113
Drug: QBECO
RxNorm normalized name: Quinolinate Benzodiazepine Ester Compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QBECO is a site specific immunomodulator (SSI) designed to promote innate immune responses in the gastrointestinal tract and related organs, including the liver. QBECO will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
Trial: NCT00499720
Drug: Aztreonam Lysine for Inhalation
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg three times a day via inhalation for 28 days followed by 28 days off drug.
Trial: NCT05677113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be prepared in the same way as the IP. Placebo will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
Trial: NCT05563038
Drug: Standard Medication Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications such as: gabapentin, duloxetine and Lyrica are all FDA approved for treatment of neuropathic pain, particularly that caused by diabetes.
Trial: NCT05642442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule(s) administered every day (QD) orally. Titration may proceed at a rate of 1 matching placebo capsule per day every 7 days as required for optimal efficacy and tolerability up to a maximum number of 3 matching placebo capsules per day.
Trial: NCT05201248
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Injection
Trial: NCT05201248
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT05401578
Drug: Placebo (0.9% NaCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml 0.9 % saline solution s.c. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
Trial: NCT05958342
Drug: saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline placebo volume matched to prehospital or in hospital phase
Trial: NCT04907851
Drug: RXC004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Trial: NCT04907851
Drug: RXC004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
Trial: NCT04907851
Drug: RXC004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Trial: NCT05869903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04895761
Drug: Cyclophosphamide 50mg
RxNorm normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral chemotherapy used in the neoadjuvant setting for Arm C only
Trial: NCT05868057
Drug: SHR7280 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR7280 tablets 1 time
Trial: NCT04716114
Drug: SKLB1028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKLB1028 will be administered by oral capsules, 150 mg twice daily (BID).
Trial: NCT06016387
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a tumour-activated antineoplastic agent (antimetabolite). The molecular formula for capecitabine is C15H22FN3O6 and has a molecular weight of 359.35 g/mol.
Trial: NCT04482712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of investigational drug placebo for up to 4 weeks while hospitalized
Trial: NCT06379399
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I:~1. 6 patients (male and female) will be enrolled to evaluate safety. Patients will receive Trifluridine/Tipiracil at a dose of 35mg/m2 (maximum single dose of 80 mg). Patients will be followed up for Dose-Limiting Toxicities (DLTs) (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 35mg/m2. If ≥3 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 30mg/m2.~2. Based on the results of the 35mg/m2 dose group, 6 patients (male and female) will be enrolled in the 30mg/m2 dose group to evaluate safety. Patients will be followed up for DLTs (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (1 Cycle, Day 1-Day 28), the study will proceed with a dose of 30mg/m2 in Phase II.~Phase II:~Trifluridine/Tipiracil: po, twice daily from Day 1-5, every two weeks, based on the recommended dose from Phase I;
Trial: NCT04940325
Drug: DS-1062a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First infusion for 90 minutes and then infusion duration can be decreased to 30 minutes if participant didn't experience infusion related reactions (IRR)
Trial: NCT05085574
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg (initial dose), then 200 mg capsule, BID for 5 days
Trial: NCT05085574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, QID for 14 days; capsule, BID for 5 days
Trial: NCT05312008
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart
Trial: NCT04706975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo administered twice daily
Trial: NCT05067283
Drug: MK-1084
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose
Trial: NCT05067283
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per label
Trial: NCT05420727
Drug: Ga-68-PSMA-11 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga-68-PSMA-11 PET/CT imaging
Trial: NCT04878406
Drug: NNC0480-0389
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.
Trial: NCT04878406
Drug: Placebo (NNC0480-0389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.
Trial: NCT04878406
Drug: Placebo (Semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.
Trial: NCT05577871
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of normal saline during the off pump coronary artery bypass grafting surgery
Trial: NCT06383767
Drug: ESG401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion on day 1,8, and 15 of each 28 day cycle
Trial: NCT05158491
Drug: JK-1201I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.
Trial: NCT05267821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See information in arm/group descriptions
Trial: NCT05983367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06265051
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.
Trial: NCT05983367
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI regimen (irinotecan 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, and then 5-FU 2400 mg/m2 over 46 hours on Days 1 and 15 of each 28-day cycle)
Trial: NCT06036914
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bumetanide will be administered via intravenous (IV) infusion at a dose of 12.5 mg two times a day (BID) for 2 doses total within 24 hours.
Trial: NCT04380831
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Undergo HSCT
Trial: NCT05802056
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05802056
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06546436
Drug: CARC-101C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects enrolled in the project will received a one-dose injection of CARC-101C
Trial: NCT06383390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06290141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: IV solution
Trial: NCT06290141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: SC solution
Trial: NCT06290141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Placebo to match intravenous immunoglobulin IVIg for IV infusio Route of administration: IV solution
Trial: NCT04920682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)\> 0.4
Trial: NCT04370145
Drug: Sulperazon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
Trial: NCT06206733
Drug: ASKB589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASKB589 will be administered as a minimum 3-hour IV infusion
Trial: NCT06206733
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally twice daily (bid).
Trial: NCT06206733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a minimum 3-hour IV infusion
Trial: NCT05177133
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO Capecitabine
Trial: NCT05251129
Drug: Pravastatin 40 Mg Oral Tablet
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower intensity statin
Trial: NCT04777331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasinezumab placebo will be administered to participants.
Trial: NCT05546853
Drug: Calcium levofolinate
RxNorm normalized name: calcium levofolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
Trial: NCT05546853
Drug: 5 FU
RxNorm normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
Trial: NCT05835895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-articular injection
Trial: NCT04881838
Drug: P regimen
RxNorm normalized name: Natural Acne Solutions 3 Step Regimen KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1
Trial: NCT04881838
Drug: Course A2 + Vin
RxNorm normalized name: PROCYANIDIN A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
Trial: NCT04881838
Drug: Course B3 +Vin
RxNorm normalized name: VITAMIN B3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
Trial: NCT04881838
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.
Trial: NCT06349057
Drug: reducing anticholinergic burden
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the intraoperative and postoperative periods instead of drugs with high anticholinergic burden; drugs with low burden will be preferred.
Trial: NCT06104839
Drug: NXC736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT06104839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT06020235
Drug: 5% Nu-3 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.